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SlOO refers to a protein fraction originally isolated from bovine brain over 25 years 
ago1 and termed SlOO to denote its partial solubility in 100% saturated ammonium 
sulfate. The bovine brain SlOO fraction is composed primarily of two small 
(M, = lO,OOO), acidic, calcium binding proteins called SlOOa and These 
proteins share approximately 50% identity in amino acid sequence and can form 
homologous and heterologous dirners of the form aa (SlOOa,), aP (SlOOa), and pp 
(S100b). The SlOOa and Sloop polypeptides are also characterized by the presence 
of regions of amino acid sequence that could form calcium binding structures: a 
conventional helix-loop-helix (EF-hand) calcium binding site in their COOH- 
terminal region and an NH2-terminal calcium binding site that resembles the site 
found in ~a lb ind in .~ .~  SlOOa and Sloop are structurally conserved in different 
species. For example, the amino acid sequences of bovine, rat, and human Sloop 
differ by only 3-4 residues (see ref. 5). Less information is available about the 
structural conservation of the S100a polypeptide, but the bovine and rat proteins 
show only four amino acid differences (see ref. 6). 
In addition to S100a and Sloop, several proteins or cDNA sequences have been 
discovered in recent years that have 30-50% sequence identity to the SlOOs. This 
family of S100-like proteins includes calcium binding proteins, proteins that are 
induced in cells after growth factor or serum stimulation, proteins increased on 
differentiation or transformation of cells, a protein subunit of a cytoskeletal protein 
complex, and serum proteins associated with diseases such as cystic fibrosis or 
rheumatoid arthritis (see ref. 7 for references). Even though these proteins share 
extensive sequence homology, little is known about their functional roles. In this 
chapter, we will concentrate on the Sloop polypeptide, the principal member of the 
SlOO family in brain. 
In both developing and mature vertebrate nervous system, Sloop is expressed 
primarily by glial cells. Although Sloop was thought to be brain specific for many 
years, it is known now that the protein is not restricted to the brain or even to nervous 
tissue. Sloop has been localized to a variety of peripheral tissues (see refs. 5, 7, and 
8), and reports about the use of Sloop localization in diagnostic pathology abound in 
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the literature. In contrast to the extensive literature about the structural properties 
and localization of Sloop, the biological roles of this protein have only recently 
begun to be elucidated. A number of intracellular functions for Sloop in glial cells 
have been suggested by in vitro studies. For example, Sloop has been reported to 
stimulate or inhibit phosphorylation of various proteins, to inhibit microtubule 
assembly, and to interact with various enzymes and cytoskeletal proteins (see ref. 7 
for references). 
In addition to these multiple intracellular activities, an increasing body of 
evidence indicates that Sloop also has extracellular roles. Sloop is known to be 
released from glial cells, being detected in brain extracellular fluid9 and in condi- 
tioned media from glial cells.lO,ll Release of Sloop from astrocytes can be stimulated 
by serotonin acting through the astrocyte 5-HTlA receptor.12 A disulfide-linked, 
dimeric form of Sloop has shown at least two extracellular activities on cultured 
cells: neurotrophic activity on select neuronal populations and mitogenic activity on 
astrocytes. Sloop stimulates enhanced survival of embryonic cortical neurons in 
culture13 and neurite outgrowth from cortical ne~rons , ’~ - l~  serotonergic neurons of 
the mesencephalic raphe,16 cells of the optic tectum,” dorsal root ganglia,ls and 
spinal cord,19 and the neuro-2A neuroblastoma cell line.20 Nanomolar concentra- 
tions of dimeric Sloop stimulate proliferation and increase in the steady-state levels 
of c-rnyc and c-fos protooncogene mRNAs in glial cells.21 Sloop was recently shown 
to be a trophic factor in vivo, being able to prevent the late naturally occurring 
motoneuron cell death during embryonic chick development as well as the deafferen- 
tation-induced death of motoneurons of the embryonic chick spinal ~ord.2~323 
Evidence to date supports the idea that Sloop is a multifunctional protein that 
plays important roles in newous system development and maintenance. Therefore, 
the mechanisms involved in regulating the intracellular versus extracellular levels of 
Sloop in the glial cell and the consequences of alterations in Sloop levels need to be 
elucidated. Sloop levels in the cell can be altered under certain conditions. For 
example, intracellular Sloop levels increase as cells become confluent and at specific 
points in the cell cycle, in response to CAMP, and on treatment with various agents 
(see refs. 7 and 24 for references). In addition, Sloop levels were reported to be 
increased in reactive glial cells of patients with Down syndrome and Alzheimer’s 
d i ~ e a s e , ~ ~ . ~ ~  a finding consistent with the localization of the gene for human Sloop to 
the Down syndrome region of chromosome 21 .27,2x Recent studies with transgenic 
mice overexpressing Sloop have demonstrated increased astroglial proliferation in 
specific areas of the brain,29 suggesting that Sloop may serve as a glial mitogen in 
vivo. 
To directly address how perturbation of Sloop levels in the glial cell correlates 
with changes in cell phenotype, we developed a biological system in which the Sloop 
levels could be decreased in a specific and reproducible manner.24 Specifically, we 
used antisense strategies to produce a selective decrease in Sloop levels in rat C6 
glioma cells. Two separate antisense approaches were used for inhibition of Sloop 
production: (1) generation of clonal isolates of C6 cells stably transfected with an 
Sloop antisense minigene under the control of a dexamethasone-inducible pro- 
moter, and (2) analysis of C6 cells treated with Sloop antisense oligodeoxynucle- 
otides. Both antisense procedures resulted in a decrease in intracellular Sloop levels 
as measured by radioimmunoassay. This lowering of Sloop levels correlated with 
three alterations in cellular phenotype: (1) a more flattened appearance, with a 
three- to fourfold increase in cellular area, (2) a more organized microfilament 
cytoskeletal network, and (3) a decrease in cellular proliferation rate. Similar results 
obtained with two distinct antisense methods provide strong evidence that Sloop has 
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important roles in glial cell morphology, cytoskeletal organization, and cell prolifera- 
tion. 
In this chapter, we briefly review the previous findings and report recent results 
examining in greater detail the effects of inhibition of glial Sloop production on cell 
morphology. 
MATERIALS AND METHODS 
Cell Culture. Rat C6 glioma cells were used throughout these studies and were 
obtained and grown as previously described.z4 These cells contain high levels of 
Sloop and have been used for many years in Sloop studies as a biological model for 
glial cells. 
Selection of Stable Clones Containing Sloop Antisense Minigene. A plasmid 
(pS100AS) containing the Sloop antisense minigene under the control of a dexa- 
methasone-inducible promoter was constructed by using a synthetic Sloop geneI5 as 
described.24 C6 cells were transfected with pSlOOAS, and colonies were selected in 
(3418, subcloned, and expanded. A number of stable clones containing the Sloop 
antisense gene construct were developed, but the majority of experiments to  date 
have used two clones, termed C6-AS1 and C6-AS2. Studies with these two clones 
yielded similar results and are used interchangeably in this chapter. 
To induce expression of the Sloop antisense gene, cells were treated for various 
times with 1 pM dexamethasone (10 pl of 1 mM dexamethasone in ethanol per 10 ml 
medium). Controls received diluent alone (10 IJ.~ of ethanol per 10 ml medium). We 
found that the endogenous Sloop levels in the C6-AS1 and C6-AS2 clones are lower 
than those in the parental C6 cells. This may merely reflect selection of clones with 
lower amounts of Sloop compared to the C6 cells, o r  the promoter may be somewhat 
‘‘leaky,’’ that is, there may be a low level of expression of the antisense gene in the 
absence of dexamethasone. In this regard, we found that it is important to use lots of 
fetal calf serum that do not contain high levels of steroid or to charcoal treat the 
serum before using in order to deplete the serum of steroids. 
Treatment of C6 Cells with S l o o p  Antisense Oligonucleotides. Oligodeoxynucle- 
otides were synthesized by p-cyanoethyl phosphoramidite chemistry as describedz4 
and were used either directly from the synthesizer or after further purification using 
Sephadex G-25 spin columns. Cells were treated with oligonucleotides as  de- 
scribed.z4 Briefly, before treatment, serum-containing medium was aspirated from 
the cells, and the cells were washed two times in serum-free medium. Cells were then 
incubated for 2 hours at 37°C in serum-free medium containing 30 IJ.M oligonucle- 
otide. After the 2-hour incubation, fetal calf serum was added to the wells (without 
changing the medium) to  a final serum concentration of 2.5%. For our studies, cells 
received only a single addition of oligonucleotide at the beginning of the time course, 
and the medium was not changed during the experiment. In our experiments, we did 
not find it necessary to use modified oligonucleotides. An important factor, however, 
is the use of lots of fetal calf serum containing low levels of nuclease activity. Before 
embarking on an oligonucleotide experiment, we carried out experiments essentially 
as described30 to test various lots of fetal calf serum for nuclease activity. We have 
had excellent results with fetal calf serum obtained from Hyclone Laboratories. 
Measurement of S loop  Levels. To confirm that Sloop production was being 
inhibited in our antisense experiments, Sloop levels were measured in cell extracts 
by radioimmunoassay, as described.24 
Analysis of Phenotypic Changes. Morphological examination of cells was per- 
formed as describedz4 or by phase-contrast microscopy on a Leitz Diavert inverted 
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microscope. The cytoskeletal proteins actin, tubulin, and vimentin were localized by 
fluorescence methods as d e s ~ r i b e d . ~ ~  Cell counts were determined with a hemacyto- 
meter. 
Time-lapse video microscopy was conducted on cells grown in a T-25 flask. The 
flask was sealed with a rubber stopper to maintain the 95% air, 5% COz atmosphere. 
Extended through the stopper was a wire (sealed in the stopper with silicone rubber 
adhesive) connected to a small thermistor that served as a temperature sensor to 
regulate an infrared source (Opti-quip Red Beam Incubator) that maintained 
temperature in the flask at 37.0 -C 0.1"C. To allow injection of dexamethasone via a 
hypodermic needle and syringe, a small hole was melted in the flask top before 
culturing cells, using a 2-mm diameter metal rod that had been heated over a bunsen 
burner. The hole was immediately sealed with silicone rubber adhesive. The adhe- 
sive cured as cells were cultured in the flask. The flask was placed on the stage of a 
Leitz Diavert inverted microscope, and cells were imaged using a long working 
distance 40x phase contrast objective lens. A Dage-MTI newvicon video camera was 
used to obtain images, and the images were recorded by a Panasonic AG6750 
time-lapse video recorder. For most studies, the recorder was set for a time 
compression of 2 4 0 ~ .  
RESULTS 
As reported previ0usly,2~ we developed two antisense methods for inhibiting the 
production of Sloop in C6 glioma cells. One method used a eukaryotic expression 
vector constructed to produce RNA complementary to the coding sequence of an 
Sloop gene. There are several key features in this Sloop antisense vector. First, the 
Sloop coding region was derived from a synthetic Sloop geneL5 that contains 77% 
homology with the coding region of rat Sloop cDNA,"' and then inserted into the 
polylinker region of the pMSVneo eukaryotic expression vector.32 Second, the 
pMSVneo vector allows the inducible expression of inserted genes, because of the 
presence of the dexamethasone-inducible promoter in the mouse mammary tumor 
virus-long terminal repeat (MMTV LTR). This was advantageous because antisense- 
containing clones could be selected before Sloop inhibition occurred, thus avoiding 
potential cloning problems due to decreases in cell growth rate. Third, pMSVneo 
contains an ampicillin resistance gene and pBR322 origin of replication, allowing 
initial cloning in bacterial cells. 
The second antisense method used Sloop antisense oligodeoxynucleotides. An 
Sloop antisense oligonucleotide was prepared whose sequence is the inverse comple- 
ment of 15 bases of the rat Sloop cDNA sequence,3I beginning at the ATG that 
corresponds to the initiator methionine. The antisense oligonucleotide had the 
sequence (reading 5' to 3'): CTCCAGCTCAGACAT. Controls included the sense 
oligonucleotide that is equivalent to the coding strand of the cDNA in this region 
(ATGTCTGAGCTGGAG), and a mismatch oligonucleotide that is equivalent to 
the antisense sequence in which two bases have been changed (CTCCACCTCA- 
GAGAT). In designing the oligonucleotides, we searched sequence databases to 
confirm that no other known nucleotide sequence matched the sequence of our 
oligonucleotides. We also kept the base composition of the mismatch oligonucleotide 
the same as the antisense oligonucleotide, making a G to C change and a C to G 
change. 
We confirmed by radioimmunoassay that both of these antisense methods 
resulted in an inhibition of Sloop production in the glial cell. FIGURE 1 summarizes 
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FIGURE 1. Inhibition of Sloop production in a C6 clone containing the Sloop antisense gene 
or in C6 cells treated with antisense oligonucleotides. In the top panel, the C6-AS2 clone (lefr) 
or untransfected C6 cells (right) were grown in the presence of dexamethasone for various 
lengths of time. Sloop levels in cell extracts were determined by radioimmunoassay, and 
calculated as ng SlOOp/Kg total protein. Sloop levels are expressed as a percentage of the 
control levels at the 0-hour time point (i.e., in the absence of dexamethasone). Bars represent 
the mean 2 SEM of four determinations (two separate experiments analyzing two wells per 
time point). In the bottom panel, C6 cells were treated with 32 FM antisense oligonucleotide 
(left) or sense oligonucleotide (right) for various lengths of time. Sloop levels were determined 
as above, and expressed as a percentage of the control levels (levels in untreated C6 cells at 
each time point). Bars represent the mean ? range of duplicate cultures from a representative 
experiment. (Figure adapted from Se l in f r e~nd .~~)  
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these data, expressed as a percentage of the control Sloop levels. It should be noted 
that by both antisense methods, Sloop levels were not significantly lower than the 
controls until between 24 and 48 hours after antisense gene induction or the addition 
of antisense oligonucleotide. This is not an unexpected finding, as Sloop is a 
relatively long-lived protein. We also could not completely inhibit Sloop production 
by either method; however, Sloop levels were only 15-20% of control values after 
72-96 hours of treatment with dexamethasone or antisense oligonucleotide. Even 
though some Sloop could be detected by radioimmunoassay at the 72- and 96-hour 
time points, we still obtained dramatic phenotypic effects of Sloop inhibition, as will 
be discussed in more detail. 
A readily observable effect of selective inhibition of Sloop production in C6 cells 
was a change in cellular morphology. An example of this morphological change is 
shown in FIGURE 2 for one of the C6 clones treated with diluent alone (a) or treated 
with dexamethasone for 48 hours (b). The C6 clone in the absence of dexamethasone 
(a) show a bipolar stellate shape typical of untransfected C6 cells, with a rounded 
and refractile appearance as the cells become confluent. After treatment of cells with 
antisense oligonucleotide (data not shown) or induction of the Sloop antisense gene 
with dexamethasone (b), the majority of cells exhibit a flattened, enlarged, and less 
refractile appearance. This change in cellular morphology was also accompanied by 
alterations in cytoskeletal organization and a decrease in cellular growth rate.24 
These phenotypic changes were not observed in untransfected C6 cells treated with 
dexamethasone or in C6 cells treated with the sense or mismatch  oligonucleotide^.^^ 
To further analyze the time course of the morphological changes that occur on 
Sloop inhibition, we examined Sloop antisense-containing clones by time-lapse 
video microscopy at various times after the addition of dexamethasone (FIG. 3). 
Before dexamethasone treatment (panels a-c), the cells exhibit rapid undulations or 
“boiling” of the cell surfaces, along with numerous areas of membrane ruffling at the 
cell edges. Cells appear small and rounded, and each cell appears to have only one 
nucleolus. Mitoses are frequent, with an average cell-cycle time of 12-14 hours 
calculated from the video images. 
After 1 day of dexamethasone exposure (panels d-f), the cell surface becomes 
more quiescent with slower undulations and fewer regions of membrane ruffling. The 
cells still undergo frequent mitoses. After 2-3 days in the presence of dexamethasone 
(panels g-i), the cells exhibit much reduced membrane activity, with very few surface 
movements or membrane ruffling. The cells are more flattened and spread, with 
larger nuclei often containing many nucleoli. Mitoses are much less frequent. From 
examination of the video images, it appears that cells may enter mitosis, but often do 
not complete cytokinesis. The resultant cells exhibit an enlarged cytoplasm and large 
nuclei containing multiple nucleoli. Estimates of cell cycle time from the few cells 
that underwent mitotis gave a value much greater than 30 hours. This lengthening of 
cell cycle time is consistent with our previous observationsz4 of a reduced rate of 
proliferation after inhibition of Sloop production. 
DISCUSSION 
Our studies demonstrate that selective inhibition of Sloop production in glial 
cells produced by using either an Sloop antisense minigene construct or Sloop 
antisense oligonucleotides is correlated with at least three phenotypic changes: (1) a 
more flattened cellular morphology, with enlarged cytoplasmic area and reduced 
membrane ruffling; (2) a more organized cytoskeleton at the level of the microfila- 
ment network; and (3) a decrease in the cellular proliferation rate. These data 
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FIGURE 2. Effects of SlOOP antisense gene induction on cellular morphology. A C6 clone 
(C6-AS2) containing the SlOOP antisense gene under the control of a dexamethasone-inducible 
promoter was grown for 48 hours in the absence (a) or presence (b) of 1 pM dexamethasone. 
Cells were examined by phase contrast microscopy. 
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support the idea that Sloop has important in vivo roles in regulation of glial cell 
morphology, cytoskeletal organization, and cell proliferation. 
Antisense strategies are becoming increasingly important tools in attempting to 
understand the function of specific gene products by inhibiting the production of the 
protein and determining the functional consequences. It should be noted that the 
Sloop genels used in our studies for construction of the antisense minigene has only 
a 77% homology with the coding region of rat Sloop cDNA. Even without complete 
homology, the antisense gene construct was able to  be used successfully to inhibit 
Sloop production in rat C6 cells, as confirmed by direct demonstration of decreased 
Sloop levels by radioimmunoassay. This finding provides a precedent for potential 
utilization of DNA sequences from one species to inhibit protein production in cells 
from another species. These data are also consistent with previous studies33 showing 
that complete DNA sequence homology is not required for inhibition of gene 
function by antisense constructs. 
The use of antisense approaches has allowed us to begin to address the in vivo 
roles of Sloop in glial cells. Our findings suggest that Sloop plays a role in regulation 
of glial cell morphology, cytoskeletal structure, and cell proliferation. The  molecular 
mechanisms by which alterations in Sloop levels lead to these phenotypic changes 
are just beginning to be explored. Our initial findings24 that a decrease in intracellu- 
lar Sloop levels resulted in a decrease in C6 cell growth rate, along with the detection 
of Sloop in conditioned media of rapidly proliferating C6 cultures,Il suggested that 
Sloop may be secreted from C6 cells to act as an autocrine growth factor. To test this 
possibility, we examined the effects of exogenous Sloop on C6 cell growth rate. We 
found2] that exogenous Sloop could stimulate C6 cell proliferation, as measured by 
both increases in (.'H)-thymidine incorporation and cell number. More recent 
studies34 have shown that Sloop evokes a transient rise in intracellular calcium and 
stimulates phosphoinositide turnover, which is consistent with the signal transduc- 
tion of other extracellular mitogenic factors. The hypothesis that Sloop antisense 
procedures slow the growth rate by decreasing production of an autocrine growth 
factor should be further tested by measuring the amount of Sloop released from C6 
FIGURE 3. Time-lapse video analysis of cellular morphology in a C6 clone containing the 
Sloop antisense gene. Cells were cultured for video recording as described in Methods, and 
grown in the absence (a-c) or  presence (d-i) of dexamethasone for various lengths of time. In 
panels a-c, the same region of the culture substrate is shown for cells grown in the absence of 
dexamethasone for - 3, 10, and 20 hours, respectively. I n  panels d-f, the same group of cells are 
shown after treatment with dexamethasone for -24, 27, and 31 hours, respectively. In panels 
g-i, cells have been treated with dexamethasone for -56.73, and 80 hours, respectively. In the 
absence of dexamethasone, cells undergo frequent mitoses (arrows in panels a-c), with a cell 
cycle time of about 13 hours. Cells treated with dexamethasone for 1 day (panels d-f) appear 
more spread and somewhat larger than untreated cells. Mitosis is still evident in occasional cells 
(arrows in f); however, the cell cycle time is significantly longer than that of untreated cells. 
After 2-3 days of dexamethasone treatment (g-h), cells are  much larger and more spread than 
untreated cells; mirosis is very infrequent (arrow in h). On those rare occasions when a cell does 
undergo mitosis, it may not go through cytokinesis. The cell indicated by the arrow in h is the 
single cell indicated by the arrow in i. After this cell went through mitosis, it did not undergo 
cytokinesis but became a daughter cell with two nuclei initially. The two nuclei then fused to 
form one larger nucleus. The infrequency of mitosis in cells treated with dexamethasone for 2 or 
more days indicates that the cell cycle time of these cells increases to much longer than 30 
hours. Assuming that the cells are still growing, the lack of mitosis may account for the large size 
of the cells and their nuclei as time in culture in the presence of dexamethasone increases. 
Bar = 50 km. 
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cells before and after inhibition of intracellular Sloop production, and by determin- 
ing if the addition of exogenous Sloop can reverse or delay the phenotypic effects of 
antisense inhibition of Sloop production. 
The precise role of Sloop in cell proliferation is not known, and it is not possible 
to exclude the involvement of intracellular functions of the protein. One of the most 
striking morphological changes resulting from a decrease in Sloop levels was the 
establishment of stress fibers, indicating a change in microfilament o rgan iza t i~n .~~  
These effects may be related to the ability of Sloop to alter interactions of actin with 
caldesmon in ~ i t r o . ~ ~  Effects of Sloop on cytoskeletal elements presumably could 
alter cell division rates. In this regard, we observed in video images of Sloop- 
antisense clones treated with dexamethasone for 2-3 days (i.e., at times when Sloop 
levels are decreased significantly) that some of the cells appeared to enter the mitotic 
cycle, but then did not complete cytokinesis (FIG. 3). This apparent arrest of cell 
division resulted in enlarged cells containing large nuclei with multiple nucleoli, and 
would help explain the reduced proliferation rate observed after Sloop inhibition. 
We have not yet pursued these observations further, but deficiencies in cytokinesis 
are very likely to result from alterations of cytoskeletal kinetics. A previous report36 
has also implicated Sloop in regulation of progression through the cell cycle. Thus, it 
is possible that Sloop plays regulatory roles during specific points in the cell cycle, 
but eludication of the mechanism of Sloop regulation will require further study. 
In summary, the available data suggest that homeostasis of Sloop levels in the 
glial cell may be critical to normal brain development and function. The ability to 
manipulate glial cells by antisense strategies to produce selective decreases in Sloop 
levels provides a useful biological system for directly testing the contribution of 
Sloop to biological processes in the brain. Our studies using antisense approaches 
have provided new insights into possible in vivo roles for Sloop in glial cell 
morphology, cytoskeletal organization, and growth regulation. In addition, these 
data provide the framework for our continuing studies aimed at defining the 
molecular mechanisms of Sloop action in nervous system development and mainte- 
nance. 
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